PEAQX tetrasodium hydrate NVP-AAM077 tetrasodium hydrate|西域试剂

PEAQX tetrasodium hydrate NVP-AAM077 tetrasodium hydrate,98.0%

产品编号：Bellancom-12294A| 分子式：C₁₇H₁₅BrN₃Na₄O₆P| 分子量：560.15

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-12294A	￥1200.00	杭州北京（现货）
Bellancom-12294A	￥2000.00	杭州北京（现货）
Bellancom-12294A	￥6400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PEAQX tetrasodium hydrate NVP-AAM077 tetrasodium hydrate

产品介绍

PEAQX (NVP-AAM077) tetrasodium hydrate 是有效的、选择性的、口服有效的 NMDA 拮抗剂，其对 hNMDAR 1A/2A 和hNMDAR 1A/2B 的 IC₅₀ 值分别为 270 nM 和 29600 nM。

生物活性

PEAQX (NVP-AAM077) tetrasodium hydrate is a potent, selective and orally active NMDA antagonist, with IC₅₀ values of 270 nM and 29600 nM for hNMDAR 1A/2B and hNMDAR 1A/2B, respectively.

体外研究

PEAQX (3 µM) produces similar caspase-3 activation, while NVP-AAM007 is approximately three-fold more potent.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PEAQX (10-40 mg/kg) dose-dependently increased cortical caspase-3 activity following sub-chronic administration.
PEAQX (10 and 20 mg/kg) shows enhanced locomotor activity in response to PCP challenge (4 mg/kg on PN28-35) compared to saline pretreatment (F_{3, 73}=4.99).
PEAQX (10 mg/kg, ip) antagonizes the effects of PRE084 on CaMKIV-TORC1-CREB and BDNF, even for learning and memory impairment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Timed, day 14 pregnant female Sprague-Dawley rats.
Dosage:	10, 20 or 40 mg/kg.
Administration:	S.C.
Result:	Showed a sensitized locomotor response to PCP challenge on PN28-35.

Animal Model:	Timed, day 14 pregnant female Sprague-Dawley rats.
Dosage:	4 mg/kg.
Administration:	I.P.
Result:	Did not significantly increase locomotor activity in rats treated sub-chronically with PEAQX on PN7, 9 and 11.

Animal Model:	11-week old C57BL/6 mice.
Dosage:	10 mg/kg.
Administration:	IP.
Result:	Reversed the effect of PRE084 (F_3,78 = 10.446, p<0.01).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Timed, day 14 pregnant female Sprague-Dawley rats.
Dosage:	10, 20 or 40 mg/kg.
Administration:	S.C.
Result:	Showed a sensitized locomotor response to PCP challenge on PN28-35.

Animal Model:	Timed, day 14 pregnant female Sprague-Dawley rats.
Dosage:	4 mg/kg.
Administration:	I.P.
Result:	Did not significantly increase locomotor activity in rats treated sub-chronically with PEAQX on PN7, 9 and 11.

Animal Model:	11-week old C57BL/6 mice.
Dosage:	10 mg/kg.
Administration:	IP.
Result:	Reversed the effect of PRE084 (F_3,78 = 10.446, p<0.01).

性状

Solid

溶解性数据

In Vitro:

H₂O : 25.5 mg/mL (45.52 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7852 mL	8.9262 mL	17.8524 mL
5 mM	0.3570 mL	1.7852 mL	3.5705 mL
10 mM	0.1785 mL	0.8926 mL	1.7852 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶